Kinoshita et al has led to an appreciation of the clinical importance of achieving regression of cardiac hypertrophy, as well as control of blood pressure, in patients receiving antihypertensive therapy. The superiority of converting enzymeinhibitors compared to other antihypertensive agents in effecting regression of cardiac hypertrophy could be attributable to their characteristic profile of actions. By inhibiting the production of A II, they not only decrease afterload through blood pressure reduction, but also ameliorate myocardial ischemia through improvement in myocardial blood flow resulting from increased myocardial and arteriolar compliance due to reduction in the size of individual myocardial cells and regression of interstitial and perivascular tissue flbrosis. Recent findings that converting enzyme inhibitors improve the prognosis for patients with heart failure can be readily understood based on the underlying pathological events leading to a hypertrophic heart.
Introduction
Congestive heart failure is characterized by the activation of several neuroendocrine systems. The increased activity of the sympathetic nervous system has already been well documented as helping to maintain systemic perfusion in the setting of ventricular dysfunction, along with the renin-angiotensin system, arginine vasopressin and endothelin (1) . To counterbalance the intense vasoconstriction and sodiumretention that are associated with these systems secretions of various vasodilator hormones, such as atrial and brain natriuretic peptides, prostaglandins and dopamine, are increased. Recent data have demonstrated that atrial natriuretic peptide suppresses the reninangiotensin system, as well as norepinephrine and endothelin, which are all associated with myocyte growth and cardiac interstitial proliferation. However, there have been no previous reports on the mechanismby which endogenousatrial natriuretic peptide regulates these vasoconstrictor hormones in the clinical setting of heart failure.
Atrial and brain natriuretic peptides in heart failure In congestive heart failure the plasma concentration of atrial natriuretic peptide (ANP) increases, due to enhanced atrial and ventricular synthesis. Circulating brain natriuretic peptide (BNP) also increases as a reuslt of enhanced ventricular production. Although ANPincreases more as the severity of heart failure progresses, BNPis more markedly elevated than ANPin severe heart failure, indicating that BNPreflects myocardial damage in addition to hemodynamic disorder (2). Gottlieb has demonstrated that the measurementofANPis an important prognostic factor in patients with chronic heart failure (3). The present study shows that while both ANPand BNPare significant predictors of survival in heart failure ( Fig. 1) , only BNPis found to be an independent predictor of mortality by the Cox proportional hazard model (ANP: ns, BNP: p=0.0015). These findings may be due to the fact that the plasma levels of BNP increase more sensitively than ANPin response to the severity of heart failure. The compensatory effects of ANPappear to be attenuated in severe congestive heart failure despite increased secretion of ANPand BNP. Plasma levels of ANPand CGMP,an intracellular second messenger of ANP,become elevated with the progression of heart failure, however in severe heart failure the plasma CGMP level has been observed to reach a plateau despite an increased level ofANP (4, 5) . Furthermore, we have demonstrated that HS-142-1 , a specific antagonist of guanylate cyclase-coupled ANPreceptors, does not change the pulmonary capillary pressure and cardiac output in severe heart failure, although it did worsen hemodynamics in mild heart failure (6, 7). This evidence may account for the depressed ANP receptor in severe heart failure.
Tissue renin-angiotensin system in aorto-caval shunt rat heart Although circulating renin-angiotensin is not always elevated in heart failure, large-scale studies of heart failure have demonstrated that the early administration of angiotensin converting enzyme inhibitor prevents morbidity and mortality in patients with heart failure. Recently, as a result of major advances in molecular biology, local synthesis of renin-angiotensin has been confirmed. Moreover, the tissue reninangiotensin system has been shown to be distinct from the circulating renin angiotensin system (8) .
Weproduced the aorto-caval shunt in rats in which circulating renin did not increase despite the elevation of plasma ANP. The expression levels of renin, angiotensinogen, angiotensinconverting enzyme, and angiotensin II types la and lb receptor mRNA were determined by the reverse transcription polymerase chain reaction (RT-PCR). The expression levels of renin or angiotensinogen and ATI receptors in the left ventricle were very low comparedto angiotensin-converting enzymemRNA in the ventricle which was found to be quite abundant. The administration of lisinopril attenuated the development of ventricular hypertrophy in this model. These results indicate the importance of converting enzyme in the formation of angiotensin II in the aorto-caval rat.
Conclusion
The main event which leads to heart failure is the loss of a critical quantity offunctional myocardial cells after an injury to the heart. Heart failure does not develop when the heart is injured but rather whenthe compensatory hemodynamicand neurohumoralmechanisms are overwhelmed or exhausted. Prolonged activation of the sympathetic nervous and reninangiotensin systems mayexert adverse effects on the heart independent of their hemodynamic action. Endogenous ANP plays a role in counteracting norepinephrine and angiotensin II in heart failure although this action is markedly attenuated in severe heart failure. The administration of angiotensin-converting enzyme or angiotensin II antagonist may reverse the downregulated ANPreceptor.
